Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

JOURNAL ARTICLE published January 2019 in The Lancet

Research funded by US National Cancer Institute: NRG Oncology Operations (grant no U10CA180868) | NRG Oncology Statistics and Data Management Center (grant no U10CA180822) | National Cancer Institute Community Oncology Research Programme (grant no UG1CA189867) | NRG Specimen Bank (grant no U24CA196067)

Authors: Maura L Gillison | Andy M Trotti | Jonathan Harris | Avraham Eisbruch | Paul M Harari | David J Adelstein | Richard C K Jordan | Weiqiang Zhao | Erich M Sturgis | Barbara Burtness | John A Ridge | Jolie Ringash | James Galvin | Min Yao | Shlomo A Koyfman | Dukagjin M Blakaj | Mohammed A Razaq | A Dimitrios Colevas | Jonathan J Beitler | Christopher U Jones | Neal E Dunlap | Samantha A Seaward | Sharon Spencer | Thomas J Galloway | Jack Phan | James J Dignam | Quynh Thu Le